Knight Therapeutics (OTCMKTS:KHTRF) Stock Jumps 3% – Here’s Why

Knight Therapeutics Inc. (OTCMKTS:KHTRF) shares rose 3% on Monday. The company traded as high as $7.94 and last traded at $7.94. Approximately 1,400 shares changed hands during trading, a decline of 81% from the average daily volume of 7,320 shares. The stock had previously closed at $7.71.

Analyst Upgrades and Downgrades

Separately, Royal Bank Of Canada reiterated an “outperform” rating on shares of Knight Therapeutics in a report on Friday, August 7th. One analyst has rated the stock with a Buy rating. According to MarketBeat.com, Knight Therapeutics has a consensus rating of “Buy”.

Knight Therapeutics Price Performance

The stock’s 50 day moving average is $7.20 and its 200 day moving average is $6.63.

About Knight Therapeutics

Knight Therapeutics Inc is a Canadian specialty pharmaceutical company focused on acquiring, licensing, commercializing and, in some cases, developing innovative prescription medicines. The company targets areas of significant unmet medical need, including oncology, rare diseases, neurology, infectious diseases and other specialty-care markets.

Knight works with pharmaceutical and biotechnology partners to bring approved or late-stage therapies to patients. Its activities generally include regulatory support, market access, commercialization and distribution rather than large-scale discovery research.